Clinical Trial Update: Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers [Phase 1]

View source ↗

Summary

Phase 1 study assessing the combination of panobinostat with sorafenib in renal cell carcinoma, soft tissue sarcoma, and non-small cell lung cancer. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• Farydak (panobinostat)
• Nexavar (Sorafenib)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Renal Cancer, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: COMPLETED